



6th International Electronic Conference on Medicinal Chemistry

1-30 November 2020

sciforum.net/conference/ECMC2020

sponsored by



pharmaceuticals

Design and synthesis of novel xanthene derivatives

**Miguel Maia ¹, Andreia Palmeira ², Diana Resende ^{1,2}, Luís Gales ^{3,4}, Madalena Pinto ^{1,2},
Emília Sousa ^{1,2*}**

¹ Medicinal Chemistry: Drug Discovery and Drug Design, CIIMAR – Interdisciplinary Centre of Marine and Environmental Research, Faculty of Porto, Porto, Portugal.

² Laboratory of Organic and Pharmaceutical Chemistry, FFUP – Faculty of Pharmacy, University of Porto, Porto, Portugal


³ Department of Molecular Biology, ICBAS - Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal

⁴ Bioengineering & Synthetic Microbiology, I3S – Instituto de Investigação e Inovação em Saúde, University of Porto, Porto, Portugal

* Corresponding author: esousa@ff.up.pt

Design and synthesis of novel xanthene derivatives

Graphical Abstract



Abstract:

Xanthenes are a special class of oxygen-incorporating tricyclic compounds. Structurally related to xanthenes, the presence of different substituents in position 9 presents a large impact on their physical and chemical properties, as well as their biological applications. Xanthene-9-carboxylic acid, 9-hydroxyxanthene (xanthinol) and their respective derivatives have been reported to exhibit remarkable biological activities, namely neuroprotection, antidiabetic, cytotoxic, and antibacterial.


Herein, we report the design of a virtual library of 300 compounds whose pharmacokinetic properties were assessed through computational tools. Synthesis strategies to obtain such drug-like xanthene derivatives - amide coupling, reductive amination, aromatic halogenation and Suzuki coupling - are described. Azaxanthenes and thioxanthenes, important xanthene bioisosters, are also considered for their capacity to establish different biologic interactions for their influence pharmacokinetic properties. Future studies will include the investigation of their potential as bioactive compounds.

Keywords: drug design, synthesis, xanthene derivatives



Introduction

Xanthenes as privileged structures



Interaction with glucocorticoid receptor the ligand binding domain¹

Interaction with the catalytic pocket of BACE1²

¹ Y. Cheng, J. Brown, T.C. Judd, P. Lopez, W. Qian, T.S. Powers, J.J. Chen, M.D. Bartberger, K. Chen, R.T. Dunn, O. Epstein, R.T. Freneau, S. Harried, D. Hickman, S.A. Hitchcock, Y. Luo, A.E. Minatti, V.F. Patel, H.M. Vargas, R.C. Wahl, M.M. Weiss, P.H. Wen, R.D. White, D.A. Whittington, X.M. Zheng, S. Wood, An Orally Available BACE1 Inhibitor That Affords Robust CNS Aβ Reduction without Cardiovascular Liabilities, ACS Medicinal Chemistry Letters, 6 (2015) 210-215.

² D.S. Weinstein, H. Gong, A.M. Doweiko, M. Cunningham, S. Habte, J.H. Wang, D.A. Holloway, C. Burke, L. Gao, V. Guarino, J. Carman, J.E. Somerville, D. Shuster, L. Salter-Cid, J.H. Dodd, S.G. Nadler, J.C. Barrish, Azaxanthene Based Selective Glucocorticoid Receptor Modulators: Design, Synthesis, and Pharmacological Evaluation of (S)-4-{5-[(1,3,4-Thiadiazol-2-yl)amino]-2-methyl-1-oxopropan-2-yl}-5H-chromeno[2,3-b]pyridin-2-yl)-2-fluoro-N,N-dimethylbenzamide (BMS-776532) and Its Methylene Homologue (BMS-791826), Journal of Medicinal Chemistry, 54 (2011) 7318-7333.

³ Y. Kwon, P. Song, J.H. Yoon, J. Ghim, D. Kim, B. Kang, T.G. Lee, J.-A. Kim, J.-K. Choi, I.K. Youn, H.-K. Lee, S.H. Ryu, Xanthene Derivatives Increase Glucose Utilization through Activation of LKB1-Dependent AMP-Activated Protein Kinase, PLOS ONE, 9 (2014) e108771.

⁴ A. Jarrahpour, E. Ebrahimi, E. De Clercq, V. Sinou, C. Latour, L. Djouhr Bouktab, J.M. Brunel, Synthesis of mono-, bis-spiro- and dispiro-β-lactams and evaluation of their antimalarial activities, Tetrahedron, 67 (2011) 8699-8704.



6th International Electronic Conference on
 Medicinal Chemistry


1-30 November 2020

sponsored:



pharmaceuticals

Results and discussion




Results and discussion

Computational prediction

Design of a virtual library of ≈ 300 molecular hybrids

- Calculation of drug likeness properties

- Lipinski's rule of five
- BBB permeation
- P-gp efflux
- CYP inhibition
- PAINS alerts



Central Nervous System (CNS) drug rules ⁷

- ✓ Molecular weight < 450
- ✓ logP < 5
- ✓ < 3 H-bond donors
- ✓ < 7 H-bond acceptors (sum of N and O)
- ✓ < 8 rotatable bonds
- ✓ TPSA < 70 Å²


⁵ Pajouhesh H, Lenz GR. Medicinal Chemical Properties of Successful Central Nervous System Drugs. *Neurotherapeutics*. 2005;2:541-553. doi:https://doi.org/10.1602/neurorx.2.4.541



Results and discussion

Synthesis


Synthesis of novel xanthene derivatives through distinctive synthetic pathways



Synthesis of derivatives

- ✓ Amide coupling
- ✓ Reductive amination
- Aromatic halogenation
- ✓ Buchwald-Hartwig cross coupling reaction
- ✓ Suzuki-Miyaura coupling


Biological applications




Results and discussion

Synthesis

Synthesis of novel xanthene derivatives through distinctive synthetic pathways



Reagents and conditions: (a) acetic acid, 25 °C; (b) anhydrous CH_2Cl_2 , DIEA, COMU, amine, 0 °C to rt; (c) anhydrous THF, TEA, TBTU, amine, rt; (d) i) $\text{BH}_3 \cdot \text{THF}$, THF, 0 °C to reflux; ii) HCl 6N, 0 °C; (e) N-chlorosuccinimide, acetic acid, HCl ; (f) Suzuki-Miyaura coupling.



Conclusions

- Computational prediction revealed promising druglike compounds with adequate pharmacokinetic properties;
- Preliminary results for the *N*-alkylation of tricyclic moieties and aromatic halogenation showed that suitable synthetic pathways were found to synthesize the desired ligands;
- Future work will focus on *in vitro* studies and further structure modifications for hit to lead optimization.



Acknowledgments



This research was supported by national funds through FCT - Foundation for Science and Technology within the scope of UIDB/04423/2020, UIDP/04423/2020, and under the project PTDC/SAU-PUB/28736/2017 (reference POCI-01-0145-FEDER-028736), co-financed by COMPETE 2020, Portugal 2020 and the European Union through the ERDF and by FCT through national funds, as well as CHIRALBIOACTIVE-PI-3RL-IINFACTS-2019. M.M. also acknowledge FCT for their PhD grant (SFRH/BD/146211/2019).



6th International Electronic Conference on
Medicinal Chemistry

1-30 November 2020

sponsored:



pharmaceuticals